1 JANUARY – 30 SEPTEMBER 2023
Strong organic growth
NET SALES
EBITA
EARNINGS GROWTH
EBITA R12 MONTHS
P/WC
Continued strong growth and improved cash flow
AddLife's growth plan is effective and we see an organic growth of 10% in the quarter. Profitability increased and the EBITA-result amounted to 12%. The operating cash flow was strengthened to SEK 138m compared to SEK 20m in the corresponding quarter of 2022. In summary, the activities to improve cash flow have been fruitful and it is gratifying that we have completed an add-on acquisition in the quarter.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
